• Saved
Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer - Prostate Cancer and Prostatic Diseases

Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer - Prostate Cancer and Prostatic Diseases

Source : https://www.nature.com/articles/s41391-022-00560-3

Metastatic castrate sensitive prostate cancer (mCSPC) is a heterogeneous disease state with variable prognosis. Although several life-prolonging systemic agents are available, there is no robust multivariable model to predict prognosis and improve risk stratification in mCSPC. The objective of this study was to build and validate a multivariable prognostic model to predict overall survival (OS) in mCSPC.


Conclusions: A prognostic model for men with de novo mCSPC was developed and validated in an independent testing set. Our model had high accuracy for predicting OS and rPFS. The model includes commonly used clinical and laboratory parameters and can guide risk stratification of these patients for participation in future trials.